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Huntington’s disease (HD) is a neurodegenerative disorder that is best known for its
effect on motor control. Mood disturbances such as depression, anxiety, and irritability
also have a high prevalence in patients with HD, and often start before the onset
of motor symptoms. Various rodent models of HD recapitulate the anxiety/depressive
behavior seen in patients. HD is caused by an expanded polyglutamine stretch in
the N-terminal part of a 350 kDa protein called huntingtin (HTT). HTT is ubiquitously
expressed and is implicated in several cellular functions including control of transcription,
vesicular trafficking, ciliogenesis, and mitosis. This review summarizes progress in
efforts to understand the cellular and molecular mechanisms underlying behavioral
disorders in patients with HD. Dysfunctional HTT affects cellular pathways that are
involved in mood disorders or in the response to antidepressants, including BDNF/TrkB
and serotonergic signaling. Moreover, HTT affects adult hippocampal neurogenesis,
a physiological phenomenon that is implicated in some of the behavioral effects of
antidepressants and is linked to the control of anxiety. These findings are consistent with
the emerging role of wild-type HTT as a crucial component of neuronal development and
physiology. Thus, the pathogenic polyQ expansion in HTT could lead to mood disorders not
only by the gain of a new toxic function but also by the perturbation of its normal function.
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INTRODUCTION
Huntington’s disease (HD) is a fatal neurodegenerative disor-
der characterized by cognitive and psychiatric disturbances that
are associated with loss of motor control, including chorea, dys-
tonia, and a lack of gestural coordination (Novak and Tabrizi,
2011). These symptoms generally start to appear in midlife. A
broad range of cognitive disturbances appear during HD progres-
sion. Early cognitive defects are characterized by poor adaptation
and planification associated with deficits in executive function-
ing and perseveration. Other defects are most prevalent during
the late stages of the disease, like learning difficulties and working
and long term memory deficits, leading to dementia (Rosenblatt,
2007; Paulsen, 2011).
HD is caused by an abnormal expansion of glutamine (polyQ)
in the N-terminal part of the 350 kDa protein huntingtin (HTT).
This stretch is encoded by a trinucleotide CAG repetition in exon
1 of HTT. An expansion greater than 36 repeats results in HD
(Huntington Collaborative Research Group, 1993). The num-
ber of repeats is inversely correlated with the age of onset of
motor symptoms and disease onset during childhood or ado-
lescence is associated with more than 60 CAG repeats (Walker,
2007). HD is inherited in an autosomal dominant manner.
Genetic and molecular studies have suggested that mutated
polyQ-HTT leads to neuronal damage by gain of toxic function.
The pathogenic mechanism requires the cleavage of full-length
HTT into smaller N-terminal fragments that contain the polyQ
stretch that have been shown to be highly toxic in HD cellular and
mouse models (Gafni et al., 2004; Graham et al., 2006). However,
there is strong evidence that loss of the normal functions of
wild-type HTT also plays a role in pathological mechanisms
of HD.
MOOD DISORDERS IN PATIENTS WITH HD
Mood disturbances are prevalent not only among patients with
diagnosed HD but also in pre-symptomatic carriers of the HD
gene (Duff et al., 2007; Julien et al., 2007; Rosenblatt, 2007)
(Table 1). These disturbances include impulsivity, irritability
(which can be accompanied by aggressiveness), anxiety, and
depression. Major depression is the most common symptom
among pre-symptomatic HD carriers, although some patients
will have only part of the symptoms of the major depression, or
limited in intensity or time (Epping and Paulsen, 2011; Reedeker
et al., 2012). Maniac depressive disorder is not particularly preva-
lent in HD (Van Duijn et al., 2008; Epping and Paulsen, 2011).
Mood disturbances may precede the onset of the motor pheno-
type by 4–10 years, making them one of the earliest symptoms of
HD. The severity of depression in HD is not dependent on disease
progression (Berrios et al., 2001; Craufurd et al., 2001; Kingma
et al., 2008). This suggests that different mechanisms affect neu-
rons involved in mood regulation and neurons involved in motor
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and cognitive skills that are disabled in late phases of the dis-
ease in HD patients. However, mood, and cognitive alterations
may also share some pathogenic mechanisms as some aspects
of these alterations are found associated in the general popula-
tion and in HD patients. In particular, depression and memory
impairments are observed together and this is also the case for
cognitive flexibility and planification defects (Smith et al., 2012;
Trivedi and Greer, 2014). Although apathy is part of symptoms
of major depression, frequency, and intensity of apathy in HD
patients increase with disease progression contrary to depression
(Kingma et al., 2008; Van Duijn et al., 2010). Thus, as previously
suggested (Levy et al., 1998), apathy appears not only as a symp-
tom of depression but as a syndrome with its own dynamics and
mechanisms.
The reasons underlying the frequent co-morbidity of HD and
mood disorder are still unclear. Family history of HD, especially
given that HD shows a dominant mode of inheritance, is proba-
bly an important factor. Indeed, an individual’s knowledge that
he or she is a carrier and will inevitably experience neurologi-
cal symptoms, could contribute to the prevalence of psychiatric
disturbances. However, this explanation alone is not sufficient to
explain the high prevalence of psychiatric disturbances in HD
(Almqvist et al., 2003; Julien et al., 2007; Van Duijn et al., 2008).
Therefore, there are probably one or several molecular mecha-
nisms, independent of the psychosocial environment, that can
explain the prevalence of mood disorders in patients or car-
riers of HD. This hypothesis can be tested in animal models
of HD.
There is no treatment that can halt or even slow down the pro-
gression of Huntington’s disease. Current effective treatments aim
to ease the symptoms of this disease. The evidence base for drugs
in HD is very small so the choice of pharmacological agents is
based mainly on clinical experience. Various molecules are used
to treat motor dysfunction. These include neuroleptics for chorea,
and tetrabenazine (which is a dopamine-depleting agent that
inhibits the vesicular dopamine transporter VMAT2) for dyskine-
sia. Tetrabenazine is the most effective drug for the management
of HD and hence is the first choice of treatment; however, this
drug induces depression and sedation in patients (Frank, 2010;
Mestre and Ferreira, 2012) and similar findings were reported in a
mousemodel of HD (YAC128) (Wang et al., 2010). Stress, anxiety,
and depression can aggravate chorea, so measures to treat these
mood problems may also help to slow the progression of HD.
Mood disorders in HD are treated by antidepressant and/or anx-
iolytic drugs (Table 1). Pre-symptomatic HD carriers are almost
twice as likely to be treated with antidepressants than individuals
who are not carriers of HD (Rowe et al., 2012). At present, there
is no established molecular evidence base for the treatment of
depression in HD. However, antidepressants are often very effec-
tive in clinical practice (Novak and Tabrizi, 2011). Depression is
most commonly treated with classic serotonin-specific reuptake
inhibitors (SSRIs) such as citalopram or sertraline. Fluoxetine is
often avoided as it exacerbates chorea and enhances anxiety, both
of which frequently occur in patients with HD (Chari et al., 2003;
Novak and Tabrizi, 2011). Anxiety is treated with non-stimulating
SSRIs such as buspirone or benzodiazepines (Novak and Tabrizi,
2011).
MOUSE MODELS OF HD
Various rodent models have been used to study the effect of polyQ
expansion in HTT (Heng et al., 2008; Pouladi et al., 2013). These
models differ in the number of CAG repeats, the size of the
expressed HTT fragment, and the gene promoter used. Thus, the
amount of mutant HTT that is expressed varies between differ-
ent models. The genetic background of the mouse strains used
to design models of HD is also important, especially because
various strains perform differently in behavioral tests (Miller
et al., 2010; Mozhui et al., 2010). These models can be grouped
according to their mode of expression of mutant HTT: transgenic
models expressing truncated HTT, transgenic models expressing
full-length HTT, and knock-in (KI) models.
The short lifespan of mouse models prevents them from devel-
oping the same neuropathological symptoms that develop during
decades in human. Large numbers of glutamines in the polyQ
stretch in the homozygous state in KI models and/or a high abun-
dance of transgenic mutant proteins are necessary to obtain a
robust phenotype. The length of the N-terminal fragments and
their toxicity are inversely correlated, which underlies the robust
phenotype of models in which a short N-terminal polyQ-HTT
fragment is expressed (Hackam et al., 1998; Landles et al., 2010).
The sequence coding the 350 kDa HTT protein contains 67
exons spanning over 170 kb of the mouse genome. Hence, the cre-
ation of transgenic models in which full-length HTT is expressed
is a difficult task. Therefore in some models, the exogenous
protein is limited to the N-terminal part containing the polyQ
expansion, with the assumption that this portion is sufficient to
recapitulate some aspects of the disease. R6/1 and R6/2 mice carry
a transgene encompassing exon 1 ofHtt (Mangiarini et al., 1996).
In R6/1 mice this exon contains a polyQ tract of approximately
115 residues whereas in R6/2 mice this number is 150. The pro-
gression of HD in R6/2 and R6/1 mice is particularly fast and
aggressive, therefore these mice may only be suitable as models
for juvenile HD, which manifests in patients with very exten-
sive polyQ stretches. These models could also correspond to the
late HD stages when HTT is cleaved and N-terminal fragments
accumulate. N171-82Q mice carry a transgene encompassing the
first 171 amino acids of HTT with a polyQ tract of 82 residues
(Schilling et al., 1999).
Transgenic models expressing full-length mutant HTT contain
the humanHTT gene with an expanded CAG repeat which is ran-
domly inserted into the mouse genome through a Yeast Artificial
Chromosome (YAC) or a Bacterial Artificial Chromosome (BAC).
The YAC72 model contains full length HTT including 72 CAG
repeats and the YAC128 model contains full length HTT includ-
ing 128 CAG repeats (Hodgson et al., 1999). Transgenic HTT
in BACHD mice contains 97 CAG repeats coding for glutamine
(Gray et al., 2008). In these models, transgenic HTT is under
the control of the human HTT promoter. The endogenous wild-
type form of HTT is still expressed in these models, which is
also the case for models expressing a truncated form of HTT.
Interestingly, mouse models expressing full-length mutant HTT
generally developmotor deficits later than transgenic models with
truncatedHTT, which allowsmore time to study anxio-depressive
behaviors without interference from motor impairment in these
mice.
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Table 1 | Clinical observations on Huntington’s disease patients.
Clinical studies
(number of patients)
Psychiatric observations Scale used to
assess depression
and/or anxiety
Use of pharmacologic
treatments
References
217 patients with motor
symptoms (comparison
black vs. white patients)
32.8% had affective disorders
Age at onset of motor symptoms for
persons with affective disorder was
significantly later than that for persons
without affective disorder (43.4 and 38.7
years, respectively).
DSM-III criteria
Diagnostic Interview
Schedule
ND Folstein et al., 1987
134 patients
Male subjects = 47%
39% were depressed
16% had attempted suicide
34% had suicidal ideation
UHDRS
PBA-HD
34% were given
antidepressant drugs.
24% were given sedative
or anxiolytic treatment
Craufurd et al., 2001
2835 patients
Male subjects = 47.5%
More than 40% of patients have
depressive symptoms.
More than 10% have attempted suicide
UHDRS More than 50% had
received antidepressant
treatments in the past
Paulsen et al., 2005
681 patients
Male subjects = 46%
More psychiatric symptoms (e.g.,
depression, anxiety,
obsessive-compulsiveness) than healthy
people.
Higher levels of psychiatric symptoms in
individuals with severe motor impairment
UHDRS
SCL-90-R
ND Duff et al., 2007
204 participants, blind to
their genetic status,
asymptomatic (definite
HD were excluded)
20% had experienced major depression
17% had an anxiety disorder, and 11% had
general anxiety.
The rate of depression increased as a
function of proximity to clinical onset
CIDI
DSM-III criteria
ND Julien et al., 2007
254 at risk of HD or
recently diagnosed
participants
Male subjects = 29%
Increased anxiety score in
presymptomatic carriers and patients with
HD individuals.
≈25% of presymptomatic carriers and
patients with HD were depressed
Prevalence of symptoms increases with
the progression of HD.
SCL-90-R
CES-D
21% were given
antidepressant, anxiolytic
or antipsychotic
treatments
Marshall et al., 2007
152 patients, including
pre-symptomatic
Male subjects = 45.5%
Higher prevalence of depression in HD
patients, including pre-symptomatic. No
higher prevalence with development of
HD
PBA-HD ND Kingma et al., 2008
154 patients including
pre-symptomatic carriers
Male subjects = 45.7%
Higher prevalence of depression/anxiety in
presymptomatic and symptomatic HD
patients than average population.
DSM-IV criteria
CIDI
26.4% were given
antidepressant treatment
Van Duijn et al., 2008
111 patients Higher prevalence of neuropsychiatric
symptoms in patients with HD than
average population. Prevalence did not
increase with the progression of HD.
PBA-HD ND Thompson et al.,
2012
803 prodromal patients
with HD mutation
Male subjects = 36%
Depression prevalence higher in females. BDI-II
SCL-90-R
UHDRS
ND Epping et al., 2013
BDI-II, Beck Depression Inventory; CES-D, Center for Epidemiological Studies Depression Scale; CIDI, Composite International Diagnostic Interview; DSM-III/IV,
Diagnostic and Statistical Manual of Mental Disorders 3rd/4th edition; PBA-HD, Problem Behaviors Assessment for Huntington Disease; SCL-90-R, Symptom
Checklist 90 Revised; UHDRS, Unified Huntington Disease Rating Scale; ND, no data.
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KI models are constructed by replacing the murine exon 1 of
the endogenous Htt gene by a chimeric human/mouse sequence
that includes various lengths of the CAG stretch (Menalled et al.,
2009). Heterozygous KIHDmice thusmimic the genetic situation
of human patients. KI models are also considered a more accu-
rate genetic HD model than many transgenic models, because
they express the mutated gene under the control of the endoge-
nous mouse promoter. Thus, the mutated HTT is expressed at
levels similar to the endogenous gene, and is not overexpressed
as in transgenic models. This may explain why KI mice have a
milder phenotype than that of transgenic mouse models. Indeed,
KI strains present very little or subtle observable motor dysfunc-
tion, and a normal lifespan (Menalled et al., 2009). KI mouse
models can be particularly useful to study the early symptoms
of the disease, including anxio-depressive disorders, prior to the
onset of motor impairments.
Few models have been developed to study the role of wild-
type HTT. The knock-out of Htt is lethal early in development at
embryonic day 7.5 (Duyao et al., 1995; Nasir et al., 1995; Zeitlin
et al., 1995); therefore, Cre-Lox systems have been used to study
the role of HTT in the developing nervous system or in the adult
nervous system (Dragatsis et al., 2000; Dietrich et al., 2009; Pla
et al., 2013). CaMKCreERT2; Htt flox/flox mice were generated to
study the function of HTT in mature cortical and hippocampal
neurons of adult mice. Following tamoxifen injection (in 2month
old mice), Htt flox/flox is excised specifically from the genome of
these neuronal cells, hence allowing the study of HTT function in
adult mice without developmental bias (Pla et al., 2013). KI mice
containing point mutations in Htt have also been produced to
study the role of post-translational modifications of HTT. These
models involve modifications of serines 1181 and 1201 that are
phosphorylated by Cdk5: mutations either mimic constitutive
phosphorylation or prevent phosphorylation at these two sites
(Ben M’Barek et al., 2013).
MOUSE MODELS OF HD PRESENT
ANXIETY/DEPRESSIVE-LIKE PHENOTYPES
The anxio-depressive status of various mouse models of HD
has been investigated by classical behavioral tests. Results are
summarized in Table 2.
ANXIETY PARADIGMS
The open-field test is frequently used to assess motor activity but
can also be applied to measure anxiety. During this test, mice
are allowed to explore a walled enclosure for about 30min. Mice
usually spend most of their time along the walls rather than
in the middle of the field, because they fear that exposure may
make them vulnerable to predators. Therefore, anxiety is inversely
correlated with the amount of time the mouse spends in the
center, and/or the number of trips it makes from the walls to
the center. It is however necessary to verify that the behavioral
differences between wild-type and HD mice in this test are not
due to an impaired motility of the HD animals. This is particu-
larly important because HDmodels (and especially the transgenic
ones) develop impairment to motor behavior. With this in mind,
the most pertinent variable to measure is the “ambulatory dis-
tance/total ambulatory distance” ratio. According to this variable,
male Hdh Q111/Q111 mice and CaMKCreERT2; Httflox/flox mice
show an anxiety-like behavior (Orvoen et al., 2012; Pla et al.,
2013). R6/2 mice and YAC128 mice also spend little time in the
center of the area (Ciamei and Morton, 2008; Chiu et al., 2011).
However, this finding may not be significant for YAC128 mice
because they also travel short distances.
The elevated plus maze (EPM) test is based on the aversion of
mice to open spaces and height, and is widely-used in the study
of anxiety behaviors. In R6/1 mice, anxiety-like behavior appears
progressively and reaches its peak in 24 week-old mice. However,
this test is difficult to interpret at this age because locomotor
activity is also altered. This impairment is shown by the small
number of entries that the mouse makes into both the open and
closed arms of the maze (Naver et al., 2003; Nithianantharajah
et al., 2008). An anxiety phenotype is observed in YAC128 mice,
which spend less time in the open quadrants of the zero-maze
than in the closed quadrants (Chiu et al., 2011). An anxiety-like
behavior is also observed in CaMKCreERT2; Httflox/flox mice (Pla
et al., 2013), showing that a loss of function of HTT only in
mature cortical and hippocampal neurons in adults is sufficient
to lead to anxiety.
The light/dark box test is used to assess anxiety-like behav-
iors and is based on the aversion of mice to light. Variables that
are measured include the latency to enter the lit compartment,
and the time spent in each compartment. Both male and female
R6/2 mice exhibit an anxiety-like behavior from 12 to 14 weeks
as assessed by this test. Anxiety may start earlier in males than
in females, although this is not a consistent finding (Hickey et al.,
2005; Menalled et al., 2009). Menalled and colleagues also showed
that 12 week-old BACHDmice spend a long time in the dark box,
indicative of an anxiety-like phenotype (Menalled et al., 2009).
CAG140 mice show a high latency to enter the lit compartment at
1.5 months of age but not at 8 months of age (Hickey et al., 2008).
This suggests that an early anxiety-like phenotype in both males
and females disappears as the disease progresses. HdhQ111/Q111 or
YAC128 mice display no phenotype in this test (Chiu et al., 2011;
Orvoen et al., 2012).
ANXIETY-DEPRESSIVE PARADIGMS
The novelty suppressed feeding (NSF) test is a conflict test with
competing motivations: the drive to eat and the fear of ventur-
ing into the center of a brightly lit area. This test measures both
anxiety and depression and the outcome of this test is sensitive to
anxiolytics and chronic antidepressants, but not to acute antide-
pressants (David et al., 2009). The NSF test is also described as
a “neurogenesis-dependent” test, because the ablation of neu-
rogenesis in the hippocampus blocks the efficacy of antidepres-
sants in this test (David et al., 2009). R6/1, HdhQ111/Q111, and
CaMKCreERT2; Htt flox/flox mice show a high latency to eat in
the NSF paradigm, suggestive of anxiodepressive-like behavior in
these mice (Renoir et al., 2011; Orvoen et al., 2012; Pla et al.,
2013).
DEPRESSIVE PARADIGMS
The sucrose preference test is used to measure anhedonia, which
is a component of depressive behavior in both humans and mice.
Studies show that HD mice have a lower preference for sucrose
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compared to wild-type mice, which represents a depressive-like
behavior (Pouladi et al., 2009; Renoir et al., 2011). This behavior
is sex-independent in YAC128 mice; however, the saccharin-
preference of R6/1 female mice is lower than that of R6/1 male
mice, or that of wild-type males or females.
In the splash test, low grooming frequency after a sucrose solu-
tion is squirted onto the mouse’s fur can be interpreted as a loss
of motivational behavior. This is thought to model some symp-
toms of depression, such as apathic behavior. Female, but not
male HdhQ111/Q111 mice, show a depressive behavior in this test
(Orvoen et al., 2012).
The forced swim test (FST) is widely used in pharmacology to
screen for molecules with anti-depressant effects. It is also used to
highlight a depressive-like behavior in rodents, linked to resigna-
tion, although the validity of this test as a measure of depression
is debatable. Apart from CAG140, all of the HD models that were
subjected to this test show a long duration of immobility, which
indicates a depressive-like behavior in this paradigm (Grote et al.,
2005; Hickey et al., 2008; Peng et al., 2008; Pouladi et al., 2009;
Chiu et al., 2011; Renoir et al., 2011; Orvoen et al., 2012; Pouladi
et al., 2012; Renoir et al., 2012). A long duration of immobility
is associated with either a short swimming duration (YAC 128)
(Pouladi et al., 2009), or a short climbing duration (HdhQ111/Q111)
(Orvoen et al., 2012). According to Detke et al. (1995) and Page
et al. (1999), short swimming duration indicates an alteration
in serotonergic circuitry and short climbing duration indicates
an alteration in noradrenergic circuitry. In the YAC128 mouse
model the severity of depressive-like phenotypes tested with FST
does not increase with age or with the progression of motor
symptoms (Pouladi et al., 2009). Furthermore, the severity of the
depressive-like phenotype is not correlated with the number of
CAG repeats (Pouladi et al., 2009), similar to the situation in HD
patients (Epping et al., 2013). There appears to be a sex-specific
component of this depressive-like phenotype. Indeed, some stud-
ies report that mutated HTT is associated with a depressive-like
phenotype in females but not in males, and in the R6/1 model,
this phenotype manifests earlier in females than in males (Grote
et al., 2005; Pang et al., 2009; Renoir et al., 2011; Orvoen et al.,
2012). Thus, in the FST, the depressive-like phenotype has a sex-
specific component, similar to findings for the sucrose-preference
test.
The tail suspension test (TST) is another widely-used test in
the screening for antidepressant drugs, and is also used to mea-
sure depressive-like behavior, linked to resignation, which is a
function of the amount of time that the animal stays immobile.
YAC128 mice show a high degree of immobility in the TST, which
is consistent with findings of the FST (Chiu et al., 2011). However,
the findings of the FST and TST involving R6/1 mice are incon-
sistent: in the TST, the duration of immobility is short for female
R6/1 mice aged 12 weeks, suggesting that mutated HTT actually
has an “antidepressant” effect (Pang et al., 2009). Nonetheless,
another study found that the HD mutation does not affect TST
performance of R6/1 mice at 8 weeks of age compared to wild-
type mice (Renoir et al., 2011). The immobility duration of male
or female CAG140 mice does not differ from that of wild-type
mice in the TST, which is consistent with FST results in this strain
(Hickey et al., 2008).
Altogether, results from different mouse strains using vari-
ous behavioral tests show that HD mice exhibit anxiety- and
depressive-like behavior. In various mouse models, a sex-specific
component to these behaviors is evident: HD mutant females
are more prone to depressive-like behaviors than mutant males
(Pang et al., 2009; Orvoen et al., 2012), whereas mutant males
are more prone to anxiety-like behaviors than mutant females
(Hickey et al., 2005; Menalled et al., 2009; Orvoen et al., 2012).
In humans, depression is roughly twice as prevalent in women as
it is inmen, and the reason of this difference is currently unknown
(Kornstein et al., 2000).
HTT, BDNF AND MOOD DISORDERS
The general functions of HTT have been recently reviewed
(Zuccato et al., 2010). Among other functions, wild-type HTT
regulates the production, transport and release of BDNF, a func-
tion that is impaired when HTT is mutated or absent (see below).
Microarray studies have shown that Bdnf+/− and forebrain-
specific Bdnf−/− mice have transcription profiles similar to those
of patients with HD or R6/2 mice (Strand et al., 2007), suggesting
a major role for BDNF in the pathogenesis of HD. BDNF has been
implicated in the physiopathology of mood disorders (Autry and
Monteggia, 2012), and is thus the most obvious candidate linking
HTT to mood disorders.
Wild-type HTT positively regulates Bdnf transcription
(Cattaneo et al., 2005). Zuccato and colleagues showed that a neu-
ron restrictive silencer element (NRSE) in the Bdnf promoter is
indirectly targeted by wild-type HTT (Zuccato et al., 2003). Wild-
type HTT inhibits the silencing activity of NRSE by sequestering
its transcription factor (REST/NRSF) in the cytoplasm, leading
to a high rate of Bdnf transcription. In contrast, in the con-
text of HD, aberrant accumulation of REST/NRSF is observed
in the nucleus, which impairs Bdnf transcription. Hence, one
of the functions of HTT is to guarantee the sufficient produc-
tion of BDNF via the sequestration of REST/NRSF. Mutated HTT
also interferes with CREB function, which is an activator of Bdnf
transcription (Zuccato et al., 2010). In agreement with these
observations, low BDNF expression has been observed in various
brain regions of HD patients, including frontal cortex, striatum,
hippocampus, substantia nigra, and cerebellum (Zuccato et al.,
2001; Seo et al., 2004). In most mouse models of HD, the abun-
dance of BDNF protein (Duan et al., 2003, 2008; Saydoff et al.,
2006; Simmons et al., 2009; Xie et al., 2010) and Bdnf mRNA is
decreased in mutant compared to normal mice in cortex, stria-
tum and hippocampus (Zuccato et al., 2005; Pang et al., 2006;
Zajac et al., 2010). It should be noted that striatal neurons express
very low amount of BDNF mRNA (Altar et al., 1997). Therefore,
the decrease of BDNF mRNA observed in striatum may not be
biologically significant (as suggested in Pang et al., 2006). The
diminished detection of BDNF at protein level in striatummay be
attributed to a transport and secretion defect of neuronal BDNF
coming from cortex or substantia nigra (see below). Studies have
reported increased BDNF protein levels in anterior cortex or sub-
stantia nigra in R6/1 mice: this may be caused by an accumulation
of BDNF linked to a transport deficit along corticostriatal or
nigrostriatal pathways (Pineda et al., 2005; Pang et al., 2006) (see
below).
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In addition to controlling the production of Bdnf mRNA,
wild-type HTT regulates BDNF transport. Gauthier and col-
leagues found that BDNF transport in microtubules is stim-
ulated by wild-type HTT (Gauthier et al., 2004). In contrast,
cortical BDNF transport is impaired both in the presence of
low amounts of wild-type HTT and by the expression of
mutant HTT (Gauthier et al., 2004). Similar findings have also
been demonstrated in hippocampal neurons (Pla et al., 2013).
Defects in BDNF vesicular trafficking decrease the activity-
dependent release of BDNF from cortical and hippocampal neu-
rons (Gauthier et al., 2004; Pla et al., 2013). This leads to the
downregulation of the phosphorylation of AKT and Erk, both of
which are regulated downstream of the interaction of BDNF with
its receptor, TrkB (Pla et al., 2013).
HTT-mediated transport is microtubule-dependent and
involves huntingtin-associated protein-1 (HAP1), which is impli-
cated in axonal transport via its interaction with the microtubule-
dependent molecular motors kinesin and dynein, as well as the
dynactin subunit p150Glued (Li et al., 1998; McGuire et al., 2006;
Rong et al., 2007). This complex is altered in the absence of HTT,
or in the presence of mutated HTT containing an abnormally
expanded polyQ tract. This alteration leads to the detachment
of BDNF vesicles from microtubules (Gauthier et al., 2004; Zala
et al., 2008).
Another argument in favor of the importance of HTT in
axonal transport involves HTT phosphorylation. Indeed, HTT
function is regulated by phosphorylation and the phospho-
rylation status of HTT affects BDNF transport and release.
Phosphorylation of HTT at serine 421 by AKT and SGK specif-
ically enhances the anterograde transport and release of BDNF at
axon terminals (Humbert et al., 2002; Rangone et al., 2004; Colin
et al., 2008). HTT is also phosphorylated at serines 1181 and
1201, which are both targets of Cdk5. In contrast to serine 421,
dephosphorylation of these sites stimulates transport and release
of BDNF (Ben M’Barek et al., 2013).
The density or the function of TrkB, the receptor for BDNF,
may also be altered due to defects in transcription and trafficking.
Indeed, the transcriptional activity of TrkB is low in HD striatal
neurons, independent of the production of BDNF (Ginés et al.,
2010). Consistent with this finding, low amounts of TrkB are
found in the caudate nucleus and/or cortex of HD post-mortem
brains (Ginés et al., 2006; Zuccato et al., 2008). In addition to
the transport of BDNF-containing vesicles, HTT also transports
TrkB-containing vesicles. The retrograde transport of activated
TrkB-containing endosomes is low in the presence of mutated
HTT, leading to an impairment in neurotrophin signaling in
striatal dendrites. This subsequently affects phospho-Erk and c-
fos within striatal neurons (Liot et al., 2013). An impairment in
Ras/MAPK/ERK1/2 signaling resulting from a low abundance of
TrkB may also be associated with the low abundance of p52/p46
Shc docking proteins in striatal cells expressing polyQ-HTT
(Ginés et al., 2010). Rab11 is also important for TrkB distribu-
tion in dendrites (Lazo et al., 2013) and defects of Rab11 recycling
endosomes have been observed in HD (Li et al., 2010).
Therefore, by dysregulating transcription, trafficking and sig-
naling at multiple levels, mutant HTT impairs both the ligand and
the receptor in the BDNF/TrkB pathway (Figure 1).
FIGURE 1 | HTT affects BDNF/TrkB signaling at many levels. HTT
regulates BDNF transcription (via the sequestration of REST/NRSF), BDNF
vesicular trafficking (via interaction with the molecular motors dynein and
kinesin), the activity-dependent release of BDNF, and also TrkB retrograde
vesicular trafficking (via HAP1 interaction). HTT also affects
Rab11-dependent endosomal recycling. HTT could also modulate TrkB
endocytosis via its interaction with HAP40 and early endosomal trafficking
via its interaction with Rab5. See references in the text.
However, the hypothesis that the impairment of the
BDNF/TrkB pathway alone can lead to mood disorder is still
a matter of debate. Most studies support the conclusion that
an impairment in the production of BDNF is not associated
with profound changes to depression-related behavior (Autry
and Monteggia, 2012). Yet, in the forced swim test and in
the sucrose preference test, female mice lacking BDNF show a
high degree of depressive-like behavior (Monteggia et al., 2007).
This is similar to the situation in HD, in which females are
more prone to depressive-like behaviors than males. In R6/1
mice, the production of BDNF is mostly affected in females,
because the abundance of a large number of Bdnf isoforms
(BDNF I, II, III, IV and VI) is low in females, whereas in
males only BDNF I and VI transcripts are affected (Zajac et al.,
2010).
In contrast, there is a clear link between anxiety-related behav-
ior and BDNF signaling. KI mice that express BDNF containing
a point mutation (valine 66 to methionine substitution, Val/Met
66) that mimics a mutation found in human populations, show
impairment in BDNF secretion and exhibit high levels of anxiety-
like behavior in open field and elevated plus maze tests (Chen
et al., 2006). Genetic or pharmacological inhibition of TrkB also
results in the modification of anxiety-related behavior (Bergami
et al., 2008; Cazorla et al., 2010). Conversely, antidepressants such
as SSRIs, tricyclic molecules, or monoamine oxidase-A inhibitors
are able to rapidly activate BDNF/TrkB signaling (Saarelainen
et al., 2003; Rantamäki et al., 2007).
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New discoveries have highlighted a role for BDNF production
and HTT in cell types other than neurons. BDNF pro-
duced by astrocytes can modify mood-related behavior in mice
(Quesseveur et al., 2013). Expression of a mutated fragment of
HTT in astrocytes causes age-dependent neurological symptoms,
including motor function deficits (Bradford et al., 2009). Anxiety
or depressive-related behaviors were not examined in these mice
and such a study would be of interest.
Finally, many studies demonstrate that the efficacy of antide-
pressant treatments depends on fully functioning BDNF pro-
duction and signaling (Monteggia et al., 2004; Malberg and
Blendy, 2005; Monteggia et al., 2007; Hu and Russek, 2008;
Li et al., 2008). Thus, restoration of the “normal” levels of
BDNF could be a therapy for HD patients. Normal levels of
BDNF can be restored by physical exercise in HD models.
According to Zajac et al. (2010), the abundance of total Bdnf
mRNA that is low in the hippocampus of both male and female
R6/1 mice is significantly increased by wheel-running activity
in female R6/1 mice and wild-type mice (but not in male R6/1
mice). Environmental enrichment is another method that pro-
motes BDNF production. Environmental enrichment is associ-
ated with a high abundance of Bdnf mRNA in the hippocampus
of male wild-type animals (Zajac et al., 2010) and environ-
mental stimulation benefits patients with HD (Sullivan et al.,
2001).
HTT AND HIPPOCAMPAL ADULT NEUROGENESIS
The amount of neurogenesis in the hippocampal dentate
gyrus (DG) is associated with anxiety state. Intriguingly, both
high or low levels of DG neurogenesis have been asso-
ciated with anxiogenic behavior, suggesting that an opti-
mal level of DG neurogenesis is important to maintain a
normal anxiety-related state (Fuss et al., 2010). Low lev-
els of neurogenesis alone are not sufficient to trigger a
depression-like phenotype; however, neurogenesis is necessary
for some of the beneficial effects of anti-depressant treatments
(Samuels and Hen, 2011; Mendez-David et al., 2014).
Neurogenesis in the subventricular zone (SVZ) is increased
in post-mortem HD brain tissue (Curtis et al., 2003). However,
neurogenesis in the DG has not been examined in HD patients.
In HD rodent models, adult neurogenesis is altered in the hip-
pocampus whereas no significant alteration of neurogenesis in the
SVZ has been observed (Gil et al., 2005; Phillips et al., 2005; Lazic
et al., 2006;). This suggests that the mechanism with which HTT
controls neurogenesis is region-specific. The discrepancy between
patients and mice regarding neurogenesis in the SVZ could be
explained by the fact that the loss of striatal neurons is more
detrimental for humans than for mice; thus, a compensatory acti-
vation of neurogenesis in the SVZ could be triggered in humans
but not in mice (Curtis et al., 2003).
HD mouse models show defects in cellular proliferation in the
DG, however these defects occur during the late stages of dis-
ease progression. In the DG of R6/1 mice, cell proliferation is
low only when mice already exhibit motor deficits (Lazic et al.,
2004, 2006; Walker et al., 2011). Similarly, YAC 128 mice show
normal cell proliferation in the DG prior to the onset of motor
deficits. However, these mice have 26% fewer proliferating cells
in the DG when they are 18 months old compared to wild-type
mice (Simpson et al., 2011). No defect in cellular proliferation
is observed for HdhQ111/Q111 mice before the onset of motor
deficits, and similarly, cellular proliferation in the loss of func-
tion CaMKCreERT2; Httflox/floxmice is not affected (Orvoen et al.,
2012; Pla et al., 2013).
In contrast to proliferation, the differentiation and sur-
vival of new-born DG neurons are affected during the early
stages of disease progression, before the onset of motor deficits.
YAC128 mice show morphological alterations to DG imma-
ture neurons (Simpson et al., 2011). Male but not female
HdhQ111/Q111 mice have defects of dendritic arborization of new-
born DG neurons (Orvoen et al., 2012). This correlates well
with anxiety-related behavior because only male HdhQ111/Q111
mice show anxiety-like behavior (Orvoen et al., 2012). This
correlation extends to the loss-of-function CaMKCreERT2;
Htt flox/floxmodel, in which anxiety-like behavior is also associ-
ated with defects of dendritic arborization and the poor long-
term survival of new-born DG neurons (Pla et al., 2013).
Conversely, in KI mice that express HTT containing non-
phosphorylatable serines 1181 and 1201, an anxiolytic-like behav-
ior is associated with an increase of dendritic arborization
and survival of newborn DG neurons (Ben M’Barek et al.,
2013).
The deletion of Htt in mature cortical and hippocampal neu-
rons affects only anxiety-related behavior and not depressive-
related behavior (Pla et al., 2013). FemaleHdhQ111/Q111 mice have
a depressive-like phenotype without perturbation of neurogenesis
(Orvoen et al., 2012). Hence in HD, depression could be related
to defects in other neuronal systems, such as raphe serotonergic
neurons (see below).
The origin of defects of hippocampal neurogenesis may be
non-cell autonomous, as is the case for CaMKCreERT2; Httflox/flox
mice. In these mice, HTT is specifically depleted in adult mature
cortical and hippocampal neurons. However, new-born neurons
show defects in dendritogenesis and survival, despite the fact that
Htt is still expressed in these neurons (Pla et al., 2013). The
phenotype of these new-born neurons is similar to that of TrkB-
depleted new-born neurons (Bergami et al., 2008). This suggests
that BDNF may be involved in the non-cell autonomous effect of
mature neurons on new-born neurons.
Natural or induced changes to the abundance of BDNF
have been associated with changes to adult hippocampal neu-
rogenesis in several studies (Lee et al., 2002; Duman, 2004;
Sairanen et al., 2005). However, although physical exercise
promotes the production of BDNF, this is not associated
with an improvement to hippocampal neurogenesis in var-
ious HD models (Kohl et al., 2007; Renoir et al., 2012).
Thus, in the context of HD, the production of BDNF does
not seem to restore normal hippocampal neurogenesis. The
exercise-dependent stimulation of neurogenesis depends on
PI3K-Akt signaling (Bruel-Jungerman et al., 2009), which acts
downstream of BDNF/TrkB. Hence, the absence of a pro-
neurogenic response to exercise in these HD models could be
linked to the aforementioned defects of BDNF/TrkB signaling.
Other players may also be involved, such as the serotonergic
system.
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HTT AND THE SEROTONERGIC SIGNALING
Dysregulation of the raphe serotonergic system has been impli-
cated as an important factor in mood disorders, including depres-
sion (Donaldson et al., 2013). Similarly, several observations
point to a dysregulation of this system in HD. A study using tran-
scranial ultrasound found a correlation between raphe echogenic-
ity and the level of depression in patients with HD (Krogias et al.,
2011). Concentrations of 5-hydroxytryptamine (5-HT) and its
metabolite 5-hydroxyindolacetic acid (5-HIAA), which are often
low in patients with major depression, are also low in HD patients
(Caraceni et al., 1977; Jongen et al., 1980), whereas the activity
of monoamine oxydase A enzyme activity (which catalyzes the
breakdown of 5-HT) is high (Richards et al., 2011). Furthermore,
5-HT binding to its receptor is also impaired, as assessed in post-
mortem HD brains (Waeber and Palacios, 1989; Steward et al.,
1993; Wong et al., 1996). The Htr1A and Htr1B receptor subtypes
appear to be particularly affected (Castro et al., 1998; Yohrling
et al., 2002). The expression of serotonergic receptors is perturbed
in murine HD models (Pang et al., 2009; Renoir et al., 2012).
The expression of Htr1a, Htr1b, and Htr2a is low, whereas the
expression of Htr2c is normal. Lower concentrations of serotonin
(and also of 5-HIAA), dopamine, and noradrenaline were found
in the striatum, cortex, and hippocampus of R6/1 mice compared
to wild-type mice (Renoir et al., 2011).
The behavior of R6/1 mice, including its sex-specific compo-
nent, resembles that ofHtr1a−/−, orHtr1b−/−, or SERT−/− mice
(Gross et al., 2000; Mayorga et al., 2001; Holmes et al., 2002; Lira
et al., 2003; Jones and Lucki, 2005). Gene expression studies have
found changes to the expression ofHtr1a,Htrb1, and SERT in the
brains of R6/1 mice (Pang et al., 2009), suggesting that alterations
of mood behavior in HD mice could be caused, at least in part,
by a low abundance of these 5-HT receptors and this 5-HT trans-
porter. The expression of Htr1b is lower in R6/1 females than in
males (Pang et al., 2009), making Htr1b an obvious candidate to
explain sex-specific differences in mood behavior. Female R6/1
mice are more sensitive than males to the Htr1a receptor ago-
nist 8-OH DPAT in the 8-OH DPAT-induced hypothermia test,
suggesting sex-specific Htr1a hypersensitivity (Renoir et al., 2011,
2012). SSRI sertraline treatment in female R6/1 mice was associ-
ated with both a reduction in depressive-like behavior and in the
hypersensitivity of Htr1a autoreceptors (Renoir et al., 2012). This
is consistent with observations in humans because sertraline is
more effective for the treatment of chronic depression in women
than in men (Kornstein et al., 2000).
It is not known if mutant HTT directly affects the transcrip-
tion of genes encoding serotonergic receptors or transporters.
However, serotonergic signaling may affect the expression of
HTT. Indeed, in Htr1a/Htr1b double KO mice, which have a
hyperserotonergic phenotype and show anxiety-related behavior,
the expression of Htt and other HD-related genes is perturbed
(Xia et al., 2012).
Serotonergic signaling can affect hippocampal neurogenesis.
This effect depends on the serotonin receptor involved, although
the overall effect is pro-neurogenic (Klempin et al., 2010).
Therefore, the low abundance of various serotonin receptors
that is observed in the hippocampus in HD models (see above)
could at least partially explain the defects in DG neurogenesis.
TrkB is expressed on serotonergic raphe neurons and BDNF pro-
duced in the hippocampus can be retrogradely transported to the
raphe (Anderson et al., 1995; Madhav et al., 2001). BDNF/TrkB
signaling affects the function of serotonergic neurons. For exam-
ple, Bdnf+/−mice show changes in serotonergic innervations of
the cortex, hypothalamus, and hippocampus (Lyons et al., 1999;
Luellen et al., 2007) and it would be interesting to examine the
densities of serotonergic innervations in HD models.
HTT AND THE HPA AXIS
The hypothalamic-pituitary-adrenal axis (HPA) is the main reg-
ulator of the stress response. In the HPA axis, cortisol secre-
tion is controlled by the hypothalamic corticotrophin releasing
hormone (CRH) and pituitary adrenocorticotropic hormone
(ACTH). Stress leads to the hyper-secretion of corticosteroids
by the adrenal glands and this is associated with a high risk of
anxiety and depression. Therefore, changes to the activity of the
HPA axis are common in patients with depression (Antonijevic,
2006). Chronic treatment of rodents with corticosterone induces
anxiety- and depression-related behavior (Ardayfio and Kim,
2006; Gourley et al., 2008; Murray et al., 2008; David et al., 2009).
The acute or chronic administration of corticosterone in mice
is associated with impairment of neurogenesis and poor neu-
ronal survival in the hippocampus (Cameron and Gould, 1994;
Karishma and Herbert, 2002; Murray et al., 2008; David et al.,
2009).
HPA hyperactivity has been observed in HD patients (Heuser
et al., 1991; Leblhuber et al., 1995; Björkqvist et al., 2006; Aziz
et al., 2009). In saliva samples taken early in the morning, pre-
symptomatic HD carriers show higher cortisol concentrations
than controls (Van Duijn et al., 2010). During the early stages of
HD, salivary concentrations of cortisol in the morning are higher
in depressed patients than in non-depressed patients (Shirbin
et al., 2013). High concentrations of cortisol have been mea-
sured in transgenic R6/2 mice (Björkqvist et al., 2006) but also
specifically in female R6/1 mice subjected to physiological or
pharmacological stresses (Du et al., 2012). This may explain the
tendency of HD female mice to have more depressive-like phe-
notypes than HD male mice in various models. Furthermore,
testosterone has a protective effect against HPA hyperactivity
(Rubinow et al., 2005).
CONCLUSIONS AND PERSPECTIVES
Studies of anxiety and depression have mainly focused on the
hippocampus, serotonergic signaling, and to a lesser extent, the
HPA axis (Figure 2). However, depression involves perturbations
of many other regions such as the prefrontal cortex, the cingu-
late cortex, the striatum, the amygdala, and the thalamus (Nestler
et al., 2002). In the context of HD, research has historically con-
centrated on perturbations to the striatum with a focus on motor
control. However, striatal alterations have also been implicated in
HD early cognitive defects like executive dysfunction (Peinemann
et al., 2005) and future studies may also implicate striatal dys-
function in mood disorders in HD patients. All these regions are
highly interconnected and mood disorders alter these circuits. It
seems reasonable to think that depression and anxiety that are
associated with HD have several origins within these circuits.
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FIGURE 2 | Many defects at various locations in the brain of HD murine
models can be linked to mood disorders. Studies in mouse models of
HD have shown that BDNF/TrkB signaling is altered in various brain regions.
Alterations of the serotonergic system and of the HPA axis have also been
documented. AG, adrenal gland; Amy, amygdala; Ctx, cortex; Hip,
hippocampus; Hyp, hypothalamus; Ra, raphe nuclei. See references in the
text.
Targeted deletion or KI mouse models could be used to answer
this question. Recently, Du et al. (2013) proposed that dysfunc-
tion of the HPA axis could trigger a cascade of events participating
to mood disorders in patients with HD.
Defects in adult hippocampal neurogenesis have also been
implicated in cognitive alteration of learning and memory, which
are also present in HD. Therefore, the study of hippocampal
neurogenesis will benefit not only our understanding of mood
alterations in patients with HD, but also our understanding of
cognitive deficits in these patients. In addition, BDNF has been
implicated in hippocampal neurogenesis but is also involved in
the development and maintenance of dendritic spines (Tyler and
Pozzo-Miller, 2003; Alonso et al., 2004; Von Bohlen und Halbach
et al., 2006, 2008), as well as synaptic plasticity (Gomez-Palacio-
Schjetnan and Escobar, 2013). Thus, defects of BDNF/TrkB sig-
naling that are described forHDmodelsmay also affect cognition.
In this regard, it is interesting to note that depression is also
associated with poor cognitive performance in patients with HD
(Smith et al., 2012).
HTT controls the intracellular trafficking of other ligands
and receptors besides BDNF and TrkB. Perturbation of this
trafficking in the presence of mutated HTT may also con-
tribute to the pathology of mood disorders For example, polyQ-
HTT alters GABAAR vesicle trafficking, resulting in the loss
of GABAAR surface delivery and in a low inhibitory synaptic
response (Twelvetrees et al., 2010; Yuen et al., 2012). GABAAR
dysfunction is implicated in mood disorders (Rudolph and
Möhler, 2014). GABA interneurons are inhibited by 5-HT1A
receptors in basolateral amygdala, an area implicated in anxiety
and fear processing (Rainnie, 1999). Moreover, NMDA receptor
signaling pathways are perturbed in HD patients (Young et al.,
1988). In transgenic YAC models of HD, alteration of NMDA
receptor activity that affects long-term potentiation (LTP) is an
early event prior to any motor or cognitive defects (Hodgson
et al., 1999; Milnerwood and Raymond, 2007).
Another level of complexity that remains to be explored is the
role of the various fragments of HTT that are generated dur-
ing the progression of HD. Mutated HTT is cleaved by caspases.
In particular, caspase-6 cleavage represents an important event
mediating neuronal dysfunction and neurodegeneration (Gafni
et al., 2004; Graham et al., 2006). YAC mice expressing a caspase-
6-resistant mutant HTT exhibit only a moderate impairment of
motor functions but also a modest depressive-like phenotype
(Pouladi et al., 2009). These data suggest that caspase-6-mediated
cleavage of HTT is an important trigger of depressive behavior. As
some N-terminal fragments do not recapitulate full-length HTT
functions, proteolysis event could be linked to the inactivation of
HTT protein function.
BDNF release and signaling is decreased in the hippocampus
in the context of HD, which is probably associated with the loss of
HTT function in vesicular transport. However, BDNF signaling is
increased in the amygdala and in the nucleus accumbens during
major depression or stress disorders (Berton et al., 2006; Krishnan
et al., 2007; Yu and Chen, 2011). Whether this is also true for
depressed or stressed patients with HD and HD mouse models
remains to be explored. If the activity of BDNF signaling is high in
the amygdala and in the nucleus accumbens in the context of HD,
then this would suggest that mutated HTT has region-specific
effects on BDNF signaling. Little is known about the functions
of HTT in the “fear” and in the reward systems where amygdala
and nucleus accumbens are implicated respectively.
The underlying unresolved question is as follows: are the
depressive symptoms observed for patients with HD different
from those of individuals without HD? In other words, are
the mechanisms at the basis of depression in patients with
HD specific to this disease? The loss of HTT specifically in
mature hippocampal neurons affects anxio-depressive behavior
and the phosphorylation of HTT at S1181/1201 also appears
to regulate mood-related behavior in mouse models of HD.
These observations suggest that HTT is part of the physio-
logical cascade controlling anxio-depressive behavior. Hence,
the interest of studying HTT extends beyond HD. HTT could
constitute a novel target for therapy in anxiety and depres-
sion both in patients with HD and in the general popula-
tion. This could be important given that the effectiveness of
currently available drugs is highly variable for many patients
(Samuels and Hen, 2011; Kupfer et al., 2012).
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